We demonstrated that inhibition of PDE4DIP is an unexpected vulnerability of KRAS-mutant CRC cells, suggesting that PDE4DIP may be a promising target for the effective treatment of KRAS-mutant CRC clinically. Here, PDE4DIP is linked to colorectal carcinoma.